Abstracts

Early Viral Suppression Improves Neurocognitive Outcomes in HIV-Infected Children

Background: Children and adolescents with perinatally-acquired HIV infection (PHIV+) are vulnerable to subtle to severe neurocognitive deficits during development. Initiation of antiretroviral therapy (ART) in infancy is associated with improved longevity; however, it is unclear if timing of ART or a specific ART regimen improves neurocognitive outcomes. Early childhood represents a sensitive period of neurodevelopment…

Role of Sulfhydryl in Causing Lytic Inactivation of HIV- 1 by Env Targeting Peptide Triazole Thiols

Background: We have identified peptide triazole thiol inhibitors which bind Env gp120, allosterically inhibit CD4 receptor and co-receptor surrogate mAb 17b binding, and cause both gp120 shedding and p24 release from the virus lumen. The prototype peptide triazole thiol KR-13 (R-I-N-N-I-X-W-S-E-A-M-M-βAQ-βA-C-CONH2, X= ferrocenyltriazole-Pro) causes p24 release, however KR-13b (C-terminal SH capped by acetomidomethyl) inhibited cell…

Identification of a Novel HIV-1 Inhibitor Targeting Vif-dependent Degradation of Human APOBEC3G

Background: APOBEC3G (A3G) is a cellular cytidine deaminase that restricts HIV replication by inducing G-to-A hypermutation in viral DNA and by deamination-independent mechanisms. Vif overcomes this innate antiviral activity by binding to A3G and targeting it for proteasomal degradation and by inhibiting its incorporation into virions. The interaction of Vif with A3G is essential for…

Drugging HIV Vif as a Rational Approach to Eradication

Background: The HIV auxiliary protein known as viral infectivity factor (Vif) enables HIV to overcome cellular APOBEC host-defense factors by binding to these proteins as a substrate receptor, thereby ensuring their ubiquitination and degradation through the 26S proteasome. Vif-Vif interaction through the PPLP domain has been shown to be ‘druggable’ in living cells using peptide…

A Novel Class of Multimerization Selective Inhibitors of HIV-1 Integrase

Background: The quinoline-based compounds are promising leads for the development of clinically useful HIV-1 integrase (IN) inhibitors, however published studies with these quinoline-based compounds have highlighted the following deficiencies: i) the A128T mutation in IN has been shown to readily develop and confer marked resistance to this class of compounds; ii) the multifunctional nature of…

Recent Progress in Developing Potent and Broadly Active HIV-1 Maturation Inhibitors

Background: A betulinic acid-based compound, bevirimat (BVM), the first-in-class HIV-1 maturation inhibitor, acts by blocking a late step in proteasemediated Gag processing: the cleavage of the capsid-spacer peptide 1 (CA-SP1) intermediate to mature CA. BVM was shown in multiple clinical trials to be safe and effective in reducing viral loads in HIV-1-infected patients. However, single-amino-acid…

HIV Pre-Exposure Prophylaxis: Clinical Pharmacology Insights

Background: HIV pre-exposure prophylaxis (PrEP) trials with tenofovir-containing regimens have achieved perfect protection in some sub-populations and no benefit in others. Pharmacological data from all PrEP trials and smaller pharmacokinetically (PK)-intensive studies provide critically useful data to help understand the larger sources of PrEP trial outcome variability, principally, highly variable adherence across studies. There is…